Saghmos’ lead product, ST-62516 (trimetazidine), is poised to enter a Phase III study as of Q3 2023 to reduce the risk of Major Adverse Cardiac and Kidney Events (MACKE) after percutaneous coronary intervention (PCI) procedures in patients with unstable angina.